Inhibition of Cell Growth and Induction of Apoptosis by<i>Antrodia camphorata</i>in HER-2/<i>neu</i>-Overexpressing Breast Cancer Cells through the Induction of ROS, Depletion of HER-2/<i>neu</i>, and Disruption of the PI3K/Akt Signaling Pathway

Chuan-Chen Lee, Hsin-Ling Yang, Tzong‐Der Way, K. J. Senthil Kumar, Ying-Chen Juan, Hsin-Ju Cho, Kai‐Yuan Lin, Li-Sung Hsu, Ssu‐Ching Chen, You-Cheng Hseu

Evidence-based Complementary and Alternative Medicine · 2012 · 34 citations · 36 references

DOIFull text

Open access

Concepts

Abstract

Previously, we demonstrated that a submerged fermentation culture of Antrodia camphorata (AC) promotes cell-cycle arrest and apoptosis in human estrogen receptor-positive/negative breast cancer cells. However, whether AC is effective against HER-2/neu-overexpressing breast cancers has not been thoroughly elucidated. In the present study, we showed that AC exhibited a significant cytotoxic effect against HER-2/neu-overexpressing MDA-MB-453 and BT-474 cells. Immunoblot analysis demonstrated that HER-2/neu and their tyrosine phosphorylation were inhibited by AC in a dose-dependent manner. An increase in intracellular reactive oxygen species (ROS) was observed in AC-treated cells, whereas antioxidant N-acetylcysteine (NAC) significantly prevented AC induced HER-2/neu depletion and cell death, which directly indicates that AC-induced HER-2/neu depletion and cell death was mediated by ROS generation. Also, AC significantly downregulated the expression of cyclin D1, cyclin E, and CDK4 followed by the suppression of PI3K/Akt, and their downstream effectors GSK-3β and β-catenin. Notably, AC-treatment induced apoptotic cell death, which was associated with sub-G1 accumulation, DNA fragmentation, mitochondrial dysfunction, cytochrome c release, caspase-3/-9 activation, PARP degradation, and Bcl-2/Bax dysregulation. Assays for colony formation also confirmed the growth-inhibitory effects of AC. This is the first report confirming the anticancer activity of this potentially beneficial mushroom against human HER-2/neu-overexpressing breast cancers.

References

36